Soleno: Mid-2024 NDA Filing For PWS Treatment Is A Major Catalyst To Watch [Seeking Alpha]
Soleno Therapeutics, Inc. (SLNO)
Last soleno therapeutics, inc. earnings: 5/13 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.soleno.life/investor-overview
Company Research
Source: Seeking Alpha
Ability to file NDA of DCCR for PWS was because of statistical significance achieved based on the primary endpoint of Study C602, which was the HQ-CT score. The global Prader-Willi Syndrome market in 2018 was estimated to be $2.11 billion in 2018. If DCCR is approved by the FDA for Prader-Willi Syndrome, it would be the first treatment of its kind to specifically target hyperphagia. Soleno Therapeutics, Inc. NASDAQ: SLNO ) is gearing up to file a New Drug Application [NDA] to the FDA of Diazoxide Choline [DCCR] for the treatment of patients with Prader-Willi Syndrome [PWS] in mid-2024. This is one major catalyst for investors Recommended For You Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
SLNO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLNO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLNO alerts
High impacting Soleno Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SLNO
News
- Soleno Therapeutics Stands with the Prader-Willi Syndrome Community [Yahoo! Finance]Yahoo! Finance
- Soleno Therapeutics Stands with the Prader-Willi Syndrome CommunityGlobeNewswire
- Soleno Therapeutics, Inc. (NASDAQ: SLNO) was upgraded by analysts at Baird R W to a "strong-buy" rating.MarketBeat
- Soleno Therapeutics, Inc. (NASDAQ: SLNO) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $65.00 to $59.00. They now have an "outperform" rating on the stock.MarketBeat
- INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Soleno Therapeutics, Inc. (SLNO) and Encourages Investors to Contact the FirmAccesswire
SLNO
Earnings
- 5/9/24 - Miss
SLNO
Sec Filings
- 5/10/24 - Form 8-K
- 5/9/24 - Form 10-Q
- 5/7/24 - Form 8-K
- SLNO's page on the SEC website